In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Coup contagion – why Africa’s had nine coups in three years
A Trudeau-Poilievre showdown as Parliament resumes
Lessons from the massive daycare E.Coli outbreak in Calgary
A multi-billion dollar bet on natural gas
What you need to know about COVID this fall
Australia resolved its news standoff with Meta. Could Canada?
The first criminal trial for ‘Freedom Convoy’ leaders
How international students became big business for schools
Canada’s wildfires dwarf emissions from all other industries
What are schools doing to help youth mental health?
Are small, family-run businesses dying in Canada?
The dark side of collagen
Ford government targets school lands to build housing
How a former Libyan dictator’s money ended up in Canada
New details emerge about Montreal’s deadliest fire in decades
What happens for Tibet when the Dalai Lama dies
Why storms are more destructive now
An ex-RCMP officer, a real estate tycoon and Operation Fox Hunt
The problem with building more housing
What it’s like to escape from wildfires
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire